Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) have received a consensus recommendation of “Moderate Buy” from the six brokerages that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $11.00.

EVAX has been the subject of a number of recent analyst reports. Weiss Ratings upgraded shares of Evaxion A/S from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, July 9th. HC Wainwright restated a “buy” rating and set a $16.00 price objective on shares of Evaxion A/S in a research report on Friday, April 24th.

Institutional Investors Weigh In On Evaxion A/S

Institutional investors have recently bought and sold shares of the business. Wesbanco Bank Inc. bought a new stake in Evaxion A/S during the fourth quarter valued at about $48,000. SmartHarvest Portfolios LLC bought a new position in shares of Evaxion A/S in the fourth quarter worth about $72,000. Northwestern Mutual Wealth Management Co. bought a new position in shares of Evaxion A/S in the fourth quarter worth about $38,000. Renaissance Technologies LLC purchased a new stake in shares of Evaxion A/S during the first quarter worth about $146,000. Finally, Rathbones Group PLC purchased a new stake in shares of Evaxion A/S during the first quarter worth about $170,000. Hedge funds and other institutional investors own 11.04% of the company’s stock.

Evaxion A/S Price Performance

EVAX stock opened at $2.82 on Monday. The business’s 50-day moving average price is $3.35 and its 200-day moving average price is $3.67. The stock has a market cap of $23.52 million, a P/E ratio of -1.92 and a beta of 0.29. The company has a quick ratio of 5.85, a current ratio of 5.85 and a debt-to-equity ratio of 0.41. Evaxion A/S has a twelve month low of $2.45 and a twelve month high of $12.15.

Evaxion A/S (NASDAQ:EVAX) last released its earnings results on Thursday, May 7th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.43). On average, equities research analysts forecast that Evaxion A/S will post -0.5 EPS for the current year.

Evaxion A/S Company Profile

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.